{"apiVersion":"1","version":"sha256:faade27e0b75b2aca6311142ff65347b4dacc153e8d28cbdf0e8a237319331f9","data":{"id":"S7682","title":"FDA OCET BAA Overview and Priorities — selected contract metadata, October 25, 2023","authors":["Robert Orr","U.S. Food and Drug Administration"],"publishedDate":"2023-10-25","format":"Report","url":"https://www.fda.gov/media/173561/download","summary":"The 2023 FDA presentation repeats 75F40120C00176 as an FDA/OMHHE collaboration studying COVID-19 illness in diverse populations. It provides a later official account of the same funding relationship described in 2022, rather than a new independent study or award. Nolan’s connection comes from the separate MaxFuse acknowledgement; no classified UAP access is reported.","subjects":["Government research funding","Medical research","Source attribution"],"people":["Garry Nolan"],"review":{"label":"Partial root native PDF text and selected layout review","scope":"Root received/hash-verified original 21-leaf FDA PDF and read native extracted leaves 1,12,17. One selected native layout actually viewed; full document graphics/layouts and executed agreements/modifications remain unreviewed. All available web-extracted text read, without complete native graphical meaning or verified live delivery.","gaps":["Full parent native layouts/graphics and complete illustrated document remain unreviewed; one selected layout viewed.","Original executed contracts, modifications, task statements and current obligations/payment history not reviewed.","Institution/project support is not a named Nolan principal-investigator finding, personal payment or classified UAP approach.","Same contract has differing award-table and later presentation descriptions; original amendment/naming history remains unknown.","Published and file metadata dates remain distinct. No operational study/protocol, patient records or claimed personal briefing reviewed."]},"familyId":"FDA-OCET-BAA-OVERVIEW-ORR-20231025","citationUrl":"https://bioparity.io/sources/S7682","citation":"Robert Orr, U.S. Food and Drug Administration. FDA OCET BAA Overview and Priorities — selected contract metadata, October 25, 2023. October 25, 2023. BioParity S7682. https://bioparity.io/sources/S7682"}}